The Signal
$IOVA's final COM-202 Cohort 1A data (62.5% ORR, 29.2% CR, OS not reached at 50.9 months) paired with pre-SITC NSCLC efficacy (expected early Nov) operationalizes a 7x TAM expansion into visible 1H27 M&A pricing. Real-world Oregon cohort (52% ORR when referred early) de-risks adoption; 150+ ATCs operationalize second-line preference by 2H27 launch, locking manufacturing + AI-dosing moat at 60%+ gross margins. Meanwhile, $INSM's DPP1 platform reframes peak-sales consensus ($7B worst-case) as floor, not ceiling—16–20% of 37M COPD/Asthma patients carry undiagnosed bronchiectasis comorbidity; INS-1033 (RA/IBD) + INS-1035 (emphysema) validate neutrophil-damage thesis across $10B+ addressable. Both trade on execution risk, not optionality.
IMPORTANT
M&A window (1H27) + platform expansion (DPP1) now operationalize; valuations have not caught up to TAM + durability signals.
What's Moving
- $IOVA (M&A catalyst sequence) — ESMO Cohort 1A final + NSCLC pre-SITC (Nov 4–8) lock $20–25 floor. 150+ ATCs + community infusion infrastructure operationalize second-line preference into 2H27 launch. Manufacturing moat removes valuation ceiling. (via @biotechscanner)
- $INSM (DPP1 as platform, not point drug) — Brinsupri $7B peak-sales ignores 500k US bronchiectasis addressable + 16–20% COPD/Asthma comorbidity adoption when scanned. INS-1033, INS-1035 validate neutrophil-damage thesis. Trading 7.6x 2027 forward vs. $RVMD 32.5x = valuation compression into flawless execution. (via @biotech2k1)
- $MIRM (Cohort 2 ATEBRIOZ durability) — Positive Cohort 2 results (pediatric 6–<12 fibrodysplasia ossificans progressiva) reinforce earlier efficacy signal; best-in-class FOP thesis holds. (via @biotech2k1 core hold)
- AI-biotech inference moat — Protein language models (AlphaFold 3 ipTM scoring, IGLOO attribution benchmarking) now operationalize residue-level variant prioritization at proteome scale. Drug repurposing confidence rivals experimentally-informed approaches. (via @biologyaidaily)
Crosscurrents
- $MRNA deflation as rotation signal — ESMO embargo breach reset narrative gravity away from mRNA novelty (intismeran 42% RRR in resectable melanoma) back to proven efficacy. Forced Sep liquidation flushed $INSM, $BBIO; bottom-buyers now rotating into fundamentals-driven immunology. Vacuum refills $IOVA, not $MRNA. (via @adamfeuerstein, @biotech2k1)
- Insurance adoption risk on Amtagvi — Real-world durability matters only if payers justify cost-per-benefit ratio in second-line refractory NSCLC. Broader ATC penetration + earlier-line penetration depend on formulary coverage velocity. (via @biotech2k1 caution)
Tradecraft
BULL
ESMO + pre-SITC Nov 4–8 catalysts lock thesis into hard optionality: OS not reached + NSCLC ORR data unlocks both strategic premium pricing and M&A floor.
WATCH
$INSM INS-1033 (RA/IBD) Phase 2 readouts + Brinsupri community ATC expansion into bronchiectasis-COPD overlap. Peak-sales rerating accelerates on comorbidity adoption proof.
Desk Notes
- @biotechscanner — $IOVA M&A + NSCLC durability operationalize; polyclonal TIL beats heterogeneous solid tumors; manufacturing moat removes ceiling.
- @biotech2k1 — $INSM DPP1 platform $10B+ TAM; $MIRM FOP best-in-class; core biotech holds through election volatility; clearing trades into pops.
- @biologyaidaily — AlphaFold 3 ipTM + IGLOO attribution now enable proteome-scale drug prioritization; inference moat operationalizes at scale.